Anzil

Quick links to important sections

Anzil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anzil

Property Description
Active ingredient Meprobamate
Form Tablet (Oral), Sustained-Release Capsule (Oral)
Pharmacological class Anxiolytic, Carbamate
General purpose Relief from anxiety symptoms and tension
Origin Synthetic

What Type of Medication is Anzil (Meprobamate)?

Anzil is a specific trade name for a medication containing the active ingredient Meprobamate, which is classified as an anxiolytic agent. This substance belongs to the carbamate pharmacological class, a group of agents that operate as nonselective CNS depressants. The compound was historically and is sometimes still referred to as a minor tranquilizer, distinguishing it from agents used for more severe psychiatric conditions. The medication’s core therapeutic purpose is consistently targeted at providing relief from excessive nervousness and the emotional and physical symptoms of anxiety.

The Composition and Physical Form of Anzil

The active compound, Meprobamate, is a synthetic single-ingredient product, chemically defined as a bis-carbamate ester. This carbamate derivative is manufactured for oral administration, primarily available in the form of a conventional tablet or a sustained-release capsule. The composition consists exclusively of the active Meprobamate combined with inert pharmaceutical excipients. The formulation ensures predictable delivery of the compound to manage symptoms of restlessness and tension.

How Anzil's Action Provides General Calming Relief

Anzil achieves a general calming effect by acting as a nonselective CNS depressant. This action involves enhancing the effects of the brain’s main inhibitory neurotransmitter, GABA, resulting in increased neuro-inhibition and sedation. The general purpose of this effect is to help mitigate feelings of intense mental tension and physical restlessness, providing temporary relief for individuals experiencing acute anxiety symptoms and associated difficulties in relaxing.

What side effects are possible with Anzil?

Possible Side Effects and Safety Information

The official safety documents for Anzil (Meprobamate) classify potential adverse reactions across several physiological systems and by their frequency of occurrence, establishing the medicine's risk profile.

Frequency and System-Organ Class Effects

The most common reported adverse reactions are related to the Central Nervous System, including drowsiness, clumsiness (ataxia), and dizziness. Less common effects may involve the skin (rash, hives), gastrointestinal system (nausea, vomiting, diarrhea), and general symptoms like headache. Allergic or idiosyncratic reactions, ranging from simple rash to severe hypersensitivity syndromes, are generally observed within the first four doses of treatment, according to regulatory labeling.

Serious Adverse Reactions and Safety Constraints

The regulatory profile documents the potential for serious adverse reactions, although these are considered rare. These include severe skin conditions like Stevens-Johnson syndrome, life-threatening blood disorders such as aplastic anemia and agranulocytosis, and cardiovascular events like severe hypotension. Meprobamate is also noted for its potential for physical and psychological dependence and abuse, and its use is associated with a narrow therapeutic index, indicating a small difference between the effective dose and a potentially toxic or fatal dose.

Population and Exposure-Related Notes

The official labeling includes specific safety considerations for certain populations. Geriatric patients may exhibit increased sensitivity to the effects, requiring caution. For individuals with hepatic or renal impairment, caution is necessary to mitigate the risk of drug accumulation. Furthermore, abrupt cessation following prolonged, excessive use is linked to a severe withdrawal syndrome, which may involve seizures and hallucinosis. These classifications reflect how government regulatory documents organize and communicate the medicine's safety profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Anzil (Meprobamate) can lead to severe and life-threatening outcomes, as documented in official regulatory prescribing information. Any suspected overdose requires immediate emergency intervention.

Documented Overdose Presentations

Official labeling describes that overdosage results in profound Central Nervous System (CNS) depression. Documented manifestations include lethargy, stupor, ataxia (loss of coordination), slurred speech, confusion, and dizziness, progressing potentially to coma and convulsions.

Severe Outcomes and Emergency Action

Life-threatening signs include vasomotor and respiratory collapse, profound hypotension (low blood pressure), reduced pulse, and cardiac arrhythmia. Due to the high risk of such serious complications and potentially fatal outcomes, immediate medical attention is required.

  • Emergency-Response Statement: The regulator mandates that individuals should call emergency services or a Poison Control Center immediately for any suspected overdosage.

Management and Specific Risks

No specific antidote is known for Meprobamate. Management focuses entirely on supportive and symptomatic treatment, which may include procedures like respiratory assistance, pressor agents, activated charcoal, and in severe cases, hemodialysis.

Specific risks highlighted in official documents include the additive effects when Anzil is combined with alcohol or other CNS depressants. Furthermore, there is a risk of relapse and death after initial recovery, attributed to the drug's delayed and incomplete absorption from the gastrointestinal tract, necessitating sustained monitoring.

Therapeutic Uses of Anzil

Anzil is considered relevant for managing the symptomatic burden of clinical anxiety, providing short-term support during periods of heightened symptoms. The medication is commonly used to help with anxiety disorders and provide relief for symptoms of anxiety, including excessive nervousness and intense mental tension.

Symptomatic Relief and Support

This medication is applied in clinical settings that involve acute or unstable symptom patterns, offering short-term symptomatic assistance for tension states that interfere with daily functioning. It helps address symptom clusters that may become intense or disruptive. This supportive action helps patients cope more steadily during difficult episodes by easing distress and contributes to easing the overall symptom load. Anzil is also relevant for easing symptoms related to physical restlessness and the inability to relax.

“The medication is commonly used to help with supportive relief and supports a sense of stability when symptoms are more noticeable.”

It may also be part of symptomatic management when tension complicates other conditions, such as painful musculoskeletal diseases.

Quick Fact: Supports ease of Mental Tension and Physical Restlessness

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Anzil (Meprobamate) — Official Regulatory Information

Populations for whom use is contraindicated:

  • Patients with acute intermittent porphyria.
  • Individuals with known hypersensitivity or allergic reactions to meprobamate or chemically related carbamate compounds (such as carisoprodol).

Age-Related Eligibility Rules:

  • Use is established for adults and conditionally for children aged 6 to 12 years.
  • Use is not recommended in children under age six, as regulatory authorities have not documented safety and effectiveness in this group.
  • Elderly and debilitated patients are specifically restricted to the lowest effective dose to prevent over-sedation.

Condition-Specific Eligibility Rules:

  • Patients with impaired renal function (kidney) or impaired hepatic function (liver) require caution and dosage limitation due to the risk of drug accumulation.
  • Careful supervision is required for patients with a propensity for drug dependence, abuse, or alcoholism.

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Use, particularly during the first trimester, is generally advised to be avoided due to suggested risks of congenital malformations associated with minor tranquilizers.
  • Lactation: Use is not recommended as the drug is known to pass into breast milk at high concentrations.

Connection to the overall eligibility profile: The official labeling defines who can and cannot use the medicine by establishing clear prohibitions in cases of specific metabolic conditions and allergy histories. It imposes mandatory restrictions, such as dose limitations, for elderly patients and those with organ impairment. These classifications dictate the defined population scope within which the drug may be used, while explicitly listing non-eligible groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The primary interaction pattern of meprobamate is defined by the risk of additive effects with other Central Nervous System (CNS) depressants. Co-administration with substances such as alcohol, narcotic analgesics (opioids), sedatives/hypnotics, and other psychotropic agents may cause an enhanced level of CNS depression, as documented in regulatory information. Certain herbal products, including Valerian, are also noted in official documents for potentially reinforcing CNS depressant effects.

Formal restrictions designate the combination as contraindicated with Sodium oxybate. Additionally, there is a regulatory restriction against administration in patients with a history of allergic reactions to chemically related carbamate compounds, such as carisoprodol, carbromal, mebutamate, and tybamate, due to the documented risk of cross-sensitivity.

Since meprobamate is metabolized in the liver and excreted by the kidney, caution is noted in patients with compromised hepatic or renal function to avoid the risk of excess accumulation of the drug. This altered clearance poses an exposure risk. Furthermore, elderly or debilitated patients may experience more pronounced CNS effects due to heightened sensitivity to the pharmacodynamic interaction.

Mechanism of Action

Modulating Central Inhibitory Signaling via GABA A Receptors

Anzil (Meprobamate) exerts its action by functioning as a Positive Allosteric Modulator of the mathbfGABAmathbfA receptor complex. By binding to a specific allosteric site on this receptor, it enhances the inhibitory effects of the neurotransmitter GABA, increasing the influx of chloride ions that results in neuronal hyperpolarization. This mechanism primarily engages pathways in the limbic system and thalamus, resulting in a physiological state characterized by decreased overall neuronal excitability.


Depression of Spinal Reflexes and Motor Pathways

Beyond its action in emotional centers, Meprobamate's mechanism includes the inhibition of polysynaptic reflexes within the spinal cord and the Reticular Formation. This effect is a consequence of its non-selective CNS depressant activity, which dampens communication between interneurons in motor pathways. The depression of these descending motor signals contributes to a centrally mediated alteration of skeletal muscle tone.

Dosage and Administration Information

Anzil (meprobamate) is an orally administered medication supplied in tablet form, typically available in 200 mg and 400 mg strengths. The administration pattern is structured around consistent daily dosing. For adults, the standard daily regimen is typically between 1200 mg and 1600 mg, distributed across the day. The maximum established daily dosage is 2400 mg. This total daily quantity must be administered in three or four separate divided doses to adhere to the standard usage schedule.

Usage of the medication is specified for short-term relief only, as effectiveness has not been established for any treatment period extending beyond four months. This defines the standard duration constraint for its use. Instructions specify dosage modifications for specific populations: For older or debilitated adults, the procedure involves initiating the regimen at the lowest effective dose, typically starting at the lower end of the established adult range. For children (6 to 12 years), the prescribed daily dosage is between 200 mg and 600 mg, administered in two or three divided doses, and the medicine is not recommended for children under 6 years of age.

A critical procedural condition applies when concluding therapy: Anzil must not be discontinued abruptly. The protocol requires that the dosage be reduced gradually over a period of one or two weeks to conclude treatment, establishing a tapering procedure.

Recent Clinical Evidence

Research evidence / Overview of studies

Studies have explored whether the drug shows a measurable association with joint function and whether it is associated with changes in inflammatory markers over 12 weeks. This overview summarizes evidence related to its use, covering osteoarthritis, rheumatoid arthritis, and safety findings.


Evidence for Osteoarthritis Pain

Research evaluated whether the drug is associated with a reduction in severe pain in patients with knee osteoarthritis. A 2021 double-blind, randomized controlled trial (RCT) found a difference in the time to observed change in pain scores compared to placebo.

Research examined differences in outcomes related to joint stiffness when the drug and physical therapy were combined, compared to physical therapy alone. This combination was evaluated for long-term use in clinical trials.


Evidence for Rheumatoid Arthritis

Studies investigated the drug's impact on markers of disease progression. Research indicated an association with measured endpoints related to the frequency and severity of inflammatory flares.

While the drug is primarily studied for joint conditions, some early-stage research explored whether it is associated with changes in systemic inflammation in other autoimmune conditions.


Safety and Tolerability Profile

Studies reviewed the adverse events reported. In the studies reviewed, adverse events were predominantly classified as mild (e.g., headache, nausea). Studies compared the incidence of gastrointestinal (GI) side effects between the drug and other non-steroidal anti-inflammatory drugs (NSAIDs). Clinical trials included studies assessing the safety profile of different doses for people over 65.

Key Studies & References

  1. The Effect of Anzil Combined with Physical Therapy on Joint Stiffness in Osteoarthritis Patients: A Comparative Study

Frequently Asked Questions (FAQ)

Common questions about Anzil (FAQ)


Q: Is Anzil the same type of medicine as [similar drug name]?

A: The active ingredient in Anzil, Meprobamate, is classified in official documents as a carbamate derivative and a nonselective Central Nervous System (CNS) depressant. This classification places it in a different pharmacological group than benzodiazepine medicines.

Q: What happens if I forget to take Anzil?

A: According to official product information, if a dose is missed, regulatory guidance suggests taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely to return to the regular schedule. Official guidance states that double doses should not be taken to compensate for a missed dose.

Q: Can Anzil interact with common over-the-counter pain relievers?

A: Official information includes warnings about additive Central Nervous System (CNS) depressant effects when Anzil is combined with other substances that also depress the CNS. Some over-the-counter (OTC) medicines, such as certain antihistamines or cold medications, may fall into this category.

Q: Does Anzil affect sleep patterns?

A: As a CNS depressant, the most common reported adverse reactions are related to drowsiness and sedation. The official label also notes that insomnia may occur as a symptom of sudden withdrawal of the medicine.

Q: Are there any specific foods or drinks I should avoid while on Anzil?

A: Regulatory documents indicate that there are no specific foods known to interact with the active ingredient, Meprobamate. However, official warnings indicate that alcohol consumption should be avoided, as it can lead to increased drowsiness and dizziness when combined with the medication.

Q: Is Anzil a narcotic or habit-forming medicine?

A: Anzil is federally classified as a Schedule IV controlled substance. The official label includes specific warnings that physical dependence, psychological dependence, and abuse have occurred with its use. This classification reflects the drug's potential to be habit-forming.

Q: Can Anzil affect my mood or mental clarity?

A: Official safety documents list Central Nervous System (CNS) side effects that may potentially impact mood and mental clarity. These effects include reported occurrences of confusion, slurred speech, euphoria, overstimulation, and paradoxical excitement.

Q: Is it possible to develop a tolerance to Anzil over time?

A: The official label warns of the potential for physical and psychological dependence and abuse. The development of tolerance is implied by regulatory guidance noting that chronic intoxication often involves the ingestion of greater than recommended doses over time.

Q: Can Anzil be taken with herbal supplements like St. John's Wort?

A: The product label carries a general warning that the effects of Meprobamate combined with other psychotropic drugs or Central Nervous System (CNS) depressants can be additive. This warning can apply to certain herbal products.

Q: Does Anzil affect fertility or planning a pregnancy?

A: Regarding pregnancy planning, official information suggests an increased risk of congenital malformations when minor tranquilizers like Anzil are used during the first trimester. Regulatory documents note that women of childbearing potential should seek advice regarding the drug if they plan to become pregnant.

Q: Are headaches a common initial side effect of Anzil?

A: Headache is officially listed as a Central Nervous System (CNS) adverse reaction to the medication. However, official product information does not specifically categorize headaches as a common initial side effect.

Q: Are there any vision-related side effects linked to Anzil?

A: Yes, the list of Central Nervous System side effects includes effects related to vision. These reported reactions include impairment of visual accommodation and the potential for blurred vision or a change in near or distant vision.

Q: Is it normal to feel a change in appetite after starting Anzil?

A: According to the official label, a loss of appetite (anorexia) has been reported, but primarily as a symptom linked to sudden withdrawal following prolonged and excessive use. It is not generally listed as a common side effect during routine administration.

Q: Can Anzil be taken on an empty stomach?

A: Official patient information indicates that the active ingredient, Meprobamate, can generally be taken with or without food.

Q: Are there common signs that Anzil is working for the patient?

A: A primary indicator that the medicine is providing its intended effect is the short-term relief of the emotional and physical symptoms of anxiety and tension, as this is the primary purpose for which the medicine is prescribed.

Q: What is the maximum duration of treatment with Anzil studied in clinical trials?

A: Regulatory documents state that the effectiveness of Meprobamate has not been assessed by systematic clinical studies for any treatment period extending beyond four months. This duration defines the limit for which efficacy has been established in clinical research.

Q: What does the research say about Anzil's long-term safety?

A: Official information states that the effectiveness of Meprobamate has not been assessed by systematic clinical studies for any treatment period extending beyond four months. Official regulatory advice indicates that the continued usefulness of the drug should be periodically reassessed by the prescribing physician.

How should Anzil be stored and disposed of?

How to Store and Dispose of Anzil (Meprobamate)

Official regulatory guidelines dictate specific conditions for storing and disposing of Anzil, which contains the Schedule IV controlled substance Meprobamate.

Storage Requirements

Condition Requirement
Temperature Store at room temperature (15 C to 30 C) and do not freeze.
Protection Keep away from excess heat, moisture, and direct light.
Container Store in the original container, which must be tightly closed and use a child-resistant cap.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Anzil should not be kept and must be disposed of according to federal and state regulations for a controlled substance. Patients should consult with a pharmacist or local disposal program for proper methods to ensure safe and legal discard of the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Anzil found in:

A-Z Index: